HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities.

Allogenic hematopoietic stem cell recipients may have preformed antibodies directed against foreign HLA antigens. The use of partially HLA-mismatched allogeneic hematopoietic stem cell donors allows for the possibility of the presence of circulating HLA donor-specific antibodies (DSAs) in the recipient. The presence of DSAs at the time of stem cell infusion increases the risk of primary graft failure. More recently developed technology using solid phase immunoassays (SPIs) with fluorochrome-conjugated beads has greatly improved the ability to detect and classify DSAs. When used in combination with the classic lymphocytotoxic complement-dependent and flow cytometric crossmatch tests, SPIs help provide DSA strength assessment. Parous females frequently harbor DSAs. DSAs tend to be of higher intensity when directed against haploidentical first-degree relatives. DSA assessment requires frequent monitoring as their relative strength can change over time. Although the criteria that constitutes a prohibitive DSA is unknown, desensitization techniques can result in engraftment rates as experienced in fully HLA-matched allogeneic blood or marrow transplantation recipients.

[1]  R. Bray,et al.  The Road to HLA Antibody Evaluation: Do Not Rely on MFI , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  Shannon R. McCurdy,et al.  Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Thall,et al.  Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  Yu Wang,et al.  Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets , 2015, Journal of Hematology & Oncology.

[5]  Shannon R. McCurdy,et al.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. , 2015, Blood.

[6]  D. Gladstone,et al.  Donor HLA-specific Abs: to BMT or not to BMT? , 2015, Bone Marrow Transplantation.

[7]  R. Pearse,et al.  A strategy to reduce donor-specific HLA Abs before allogeneic transplantation , 2014, Bone Marrow Transplantation.

[8]  Andrea A Zachary,et al.  Desensitization for solid organ and hematopoietic stem cell transplantation , 2014, Immunological reviews.

[9]  M. Krajinovic,et al.  The Clinical Relevance of Pre-Formed Anti-HLA and Anti-MICA Antibodies after Cord Blood Transplantation in Children , 2013, PloS one.

[10]  D. Hanau,et al.  Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d’Histocompatibilité et d’Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire ( , 2013, Haematologica.

[11]  H. Saji,et al.  Rapid hematopoietic recovery with high levels of DSA in an unmanipulated haploidentical transplant patient. , 2013, Transplantation.

[12]  A. Zachary,et al.  Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  H. Tamaki,et al.  Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT , 2012, Bone Marrow Transplantation.

[14]  A. Zachary,et al.  HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls. , 2012, Methods in molecular biology.

[15]  J. Ritz,et al.  Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. , 2011, Blood.

[16]  P. Thall,et al.  Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. , 2011, Blood.

[17]  J. Wagner,et al.  Anti-HLA antibodies in double umbilical cord blood transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  O. Ringdén,et al.  Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. , 2011, Transplant immunology.

[19]  L. Kucirka,et al.  Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.

[20]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[21]  H. Azuma,et al.  The impact of anti-HLA antibodies on unrelated cord blood transplantations. , 2010, Blood.

[22]  R. Stuart,et al.  Overcoming HLA‐DPB1 donor specific antibody‐mediated haematopoietic graft failure , 2010, British journal of haematology.

[23]  J. Klein,et al.  The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. , 2007, Blood.

[24]  S Mackinnon,et al.  Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles , 2010, Leukemia.

[25]  P. Thall,et al.  High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation , 2009, Transplantation.

[26]  D. Segev,et al.  Proinflammatory Events Are Associated with Significant Increases in Breadth and Strength of HLA‐Specific Antibody , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  J. Serody,et al.  Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. , 2007, Blood.

[28]  R. Montgomery,et al.  Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. , 2005, Human immunology.

[29]  B. Kremens,et al.  Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation , 2002, Transplantation.

[30]  K. Sullivan,et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.